StockData
Protagonist Therapeutics, Inc logo

Protagonist Therapeutics, Inc (PTGX) company profile

PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$124.67−0.16 (-0.13%)

Close on Nov 17, 2026Market cap $8.07BP/E 121.0Yield –

About Protagonist Therapeutics

Pharmaceutical Preparations, SIC 2834

Protagonist Therapeutics is an integrated biopharmaceutical company focused on discovering and developing differentiated peptide-based medicines. The company organizes its research across three core therapeutic segments: inflammation and immunology, hematology, and metabolic diseases. Key development-stage assets include icotrokinra for plaque psoriasis, rusfertide for polycythemia vera, and preclinical candidates targeting obesity and related conditions. Operating primarily through strategic partnerships, Protagonist collaborates with major multinational pharmaceutical corporations such as Janssen Biotech and Takeda Pharmaceuticals for Phase 2 and Phase 3 development, regulatory submissions, and commercialization.

The company engages in clinical development and regulatory activities spanning the United States and Europe, supported by worldwide licensing and collaboration structures. Its late-stage candidates have been submitted for regulatory review to both the U.S. Food and Drug Administration and the European Medicines Agency. The provided text does not state the company's headquarters location or the physical count of its operating facilities.

Summary of the business section of Protagonist Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Protagonist Therapeutics, Inc
Headquarters
Newark, CA
Address
7707 Gateway Blvd., Suite 140 94560-1160
Phone
(510) 474-0170
Employees
132, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Mateo, California, USA

Stock & identifiers

Ticker
PTGX
Exchange
Nasdaq
IPO date
Aug 12, 2016
Shares outstanding
65M, Jul 31, 2026
Public float
$2.90B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1377121
CUSIP
74366E102
ISIN
US74366E1029
FIGI
BBG002B63KM7
Share class FIGI
BBG002B63KP4
EIN
98-0505495

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Dinesh V. Ph D. PatelPresident and CEO, Director522,968
Arturo Molina MdChief Medical Officer81,397
Asif AliChief Financial Officer59,003
Suneel GuptaChief Development Officer267,433
William D. WaddillDirector7,825
Bryan GiraudoDirector12,695
Harold E. SelickDirector84,845
Lewis T. WilliamsDirector7,825
Sarah A. O'DowdDirector7,825

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$12.87M$46.07M$3.68M$433$125
FY2024$9.47M$17.93M$3.00M$191$93
FY2023$7.07M$15.33M$1.81M$114$94
FY2022$5.99M-$5.17M$2.47M$54$90
FY2021$5.54M$12.11M$2.22M$170$100

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Dinesh V. Patel, Ph.D.
President and Chief Executive Officer
$715.50K$5.84M$5.62M$686.88K$11.91K$12.87M+36%
Asif Ali
EVP, Chief Financial Officer
$500.00K$1.24M$1.19M$320.00K$6.24K$3.26M+16%
Arturo Molina, M.D., M.S., F.A.C.P.
Chief Medical Officer
$572.00K$1.60M$1.54M$366.08K$11.91K$4.10M+18%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Aug 12, 2016
Offer price
$12.00
Securities offered
7,500,000
Gross proceeds
$90.00M
Exchange
Nasdaq
First trading day
Aug 11, 2016
First-day close
$11.70-2.5%
Lock-up ends (est.)
Feb 7, 2017

“The initial public offering price is $12.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, our total global workforce consisted of 132 full-time equivalent employees, 103 of whom were in research and development.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jul 3, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 18, 2020Auditor changeChange in certifying accountant (8-K Item 4.01)
Aug 12, 2016IPOInitial public offering priced (424B4 prospectus)
Aug 5, 2016ListingRegistration of securities on an exchange (Form 8-A)
Sep 28, 2006Name changeName changed from Protagonist Inc to Protagonist Therapeutics Inc

See a number that looks wrong?